Chamber and committees

The exact data requested is not held. The Cancer Waiting Times data does not report on average waits, however median waits are reported. The information below is for urological cancers and is provided both for 62-day and 31-day standard. The 62-day standard refers to ‘urgent’ referrals only and waiting times are from ‘urgent’ referral to the start of their first treatment for a newly diagnosed cancer. The 31-day standard is for ‘all’ referrals and waiting times are from the decision to treat to the start of their first treatment for a newly diagnosed cancer. Please note: the waiting times for 62-day and 31-day standards are not comparable as both standards refer to different cohorts of patients.

The Median length of wait between referral to first treatment (62-day standard) for urology cancers in 2017 was 49 days, 47 days in 2018, 45 days in 2019, 39 days in 2020 and 44 days in 2021.

The Median length of wait between decision to treat and first treatment (31-day standard) for urology cancers in 2017 was 12 days, 13 days in 2018, 11 days in 2019, 8 days in 2020 and 11 in 2021.

To note the median values for the year 2021 are based on the data that has already been published i.e. data for the months of January- September 2021.

The Scottish Government is committed to developing and implementing within this parliamentary term a revised contracting framework for community pharmacy NHS pharmaceutical services, underpinned by a review of existing Control of Entry, funding arrangement and introduction of a Performers List for the Pharmacy profession, as outlined in Achieving excellence in pharmaceutical care: a strategy for Scotland strategy.

Any future amendments to the regulations will uphold the necessity for successful applications to be granted around set criteria. These include neighbourhood requirements, the adequacy of existing pharmaceutical services in an area (from registered pharmacy premises), and the necessity or desirability of to secure adequate pharmaceutical services in an area.

Information on the number of diagnostic procedures performed in NHS Scotland is available on the Public Health Scotland website and can be found in the Acute Hospitals and Finance Cost Books . However, the activity data published for radiology in the Finance Cost Books is reported with elective and emergency totals combined, which does not allow us to report on elective diagnostics activity disaggregated. Further, the Acute Hospitals publication only publishes activity data on particular endoscopy tests, therefore it cannot give us a complete picture for endoscopy activity. Data on the ongoing waits of diagnostic procedures can be found in the PHS Diagnostics publication .

We have provided £29 million to support an increase in diagnostic procedures by 78,000 during the current year and expect diagnostic capacity to increase by at least 90,000 procedures per year by the end of the NHS Recovery Plan in 2025/26. This equates to 29,000 additional CT scans, 24,000 MRI scans and 25,000 additional endoscopy procedures by the end of the Plan.

The information requested is not held centrally by the Scottish Government or by Public Health Scotland, however confirmed cervical cancer patients being treated on the 31 day or 62 day pathway, with their waiting times, can be found at:

Cancer waiting times - 1 July to 30 September 2021 - Cancer waiting times - Publications - Public Health Scotland

We do not have the information requested as we are still in the test phase of this programme. In this government’s first 100 days, we established ten pilot schemes to test how best to provide free bikes for school age children who cannot afford one. These pilots will run for up to 12 months, testing different approaches and delivery models which will then be independently evaluated to help inform a national rollout. Of the mentioned council areas, Shetland is currently covered by one of the ten pilots. The pilot team in Shetland have procured their first 25 bikes, and are now preparing their distribution.

Colposcopy capacity has been impacted by Covid-19, regrettably resulting in longer than usual waiting times in some Health Boards.

In recognition of this, last year we provided over £660,000 additional funding to NHS Ayrshire & Arran, NHS Greater Glasgow & Clyde, NHS Highland, NHS Lothian and NHS Tayside to support capacity in colposcopy provision. The funding was used to enhance capacity through additional workforce and extra clinics, including at weekends.

We will continue to work closely with Boards who are facing challenges in order to remobilise services as soon as possible.

The Cancer Survival publication is due for release on 19th April 2022 and will be hosted by Public Health Scotland. Data on 1 and 5 year survival will be published for patients diagnosed between 2015 and 2019 as well as long-term trends in survival for patients diagnosed since 1995. Information is presented for 27 types of cancer, for Scotland as a whole and by age, sex and socio-economic deprivation.

The Scottish Government recognises that island communities can face distinct challenges in the transition to zero emissions heating. We are committed to continuing to make higher levels of funding available per head through our energy efficiency/fuel poverty delivery programmes in remote rural areas, where we know installation and labour costs are higher.

Through our Islands Energy Strategy – of which a draft is due to be published later this year, we will work with stakeholders to take an evidence based approach to explore the need additional support for those rural and island homes which require bespoke and targeted advice for heat and energy efficiency.

Furthermore, our Heat in Buildings Supply Chain Action Plan, due to be published later this year will include a specific focus on developing local supply chains, including in our islands and remote communities, to help bring costs down.

There is an existing ScotRail Stakeholder Advisory Panel on which passenger representatives sit, that will continue with the new company, and whose chair will attend the ScotRail Trains Limited Board in the same manner as they do presently.

Passenger Focus, the passenger representative body for all forms of transport in Scotland and the UK sit on the ScotRail Stakeholder Advisory Panel, along with other stakeholder representatives including various Chamber of Commerce representatives, Inclusion Scotland, representative from the Academic sector, Transport Focus and representation from Community Rail Partnerships in Scotland. The Chair of the ScotRail Stakeholder Advisory Panel, CBI’s Scotland Director, will sit on the ScotRail Trains Limited Board and provide the collective stakeholder input to Board decisions.

The Scottish Government is also launching a National Conversation to encourage passengers, rail staff and other stakeholders to play their part in shaping the future of rail passengers services in Scotland.

The majority of investment has been in relation to the Stirling-Dunblane-Alloa electrification and improvement work, and I refer the member to the answer to question S6W-05903 on 21 february 2022 for that detail. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

In addition to the referenced rail investment, we have awarded £500,000 through our Bus Partnership Fund to the Forth Valley Bus Alliance for improvement on key bus corridors in the region. £230,000 of this funding will look at key bus corridors in Stirling.